Fierce Pharma
DECEMBER 6, 2023
With an FDA approval in PNH, Novartis has gained its first nod for iptacopan, dubbed two months ago “a pipeline in pill," by analysts at ODDO BHF.
MedCity News
DECEMBER 6, 2023
CB Insights released a list of what it deems to be the 50 most promising digital health companies of 2023. The market research firm said that the startups on the list are working to improve four main aspects of healthcare: personalization, efficiency, equity and accessibility.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 6, 2023
After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. | In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. Many years later, Novartis is settling the case.
MedCity News
DECEMBER 6, 2023
Canopy has emerged from stealth as a startup focused on protecting healthcare staff from increasing levels of violence. The company’s product, called Canopy Protect, involves wearable monitors that healthcare staff can press when they feel threatened, as well as a system that allows a hospital to monitor all physical areas of the organization.
Fierce Pharma
DECEMBER 6, 2023
Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. | Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial.
PharmExec
DECEMBER 6, 2023
Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 6, 2023
Seattle Children's launched BrainChild Bio to focus on expediting the development of CAR T-cell therapies in central nervous system tumours.
MedCity News
DECEMBER 6, 2023
Through rigorous validation processes, unwavering transparency, gradual implementation, and a steadfast commitment to preserving the human touch, healthcare IT providers can unequivocally demonstrate that AI is a reliable and trustworthy ally in the intricate and evolving landscape of healthcare.
PharmExec
DECEMBER 6, 2023
National Library of Medicine study emphasizes inadequacies in ensuring the safety and efficacy of over-the-counter dietary supplements.
MedCity News
DECEMBER 6, 2023
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
DECEMBER 6, 2023
The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Novartis’ Factor B inhibitor, Fabhalta ® (iptacopan) provides comprehensive control of red blood cell (RBC) destruction, according to the company. Novartis releases data for potentially “practice-changing” PNH medicine Key Phase III data for iptacopan “In clinical studies, iptacopan was superior to anti-C5s in haemoglobin improv
MedCity News
DECEMBER 6, 2023
Dr. Wendaline VanBuren, a radiology chair at Mayo Clinic, thinks that AI is in the beginning stages of improving radiologists’ workflows. Some of the most developed radiology AI research projects at Mayo center on image segmentation and 3D printing, she said. In the future, she’s excited to see more tools that aid radiologists in triage and lesion measurement.
Pharmaceutical Technology
DECEMBER 6, 2023
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
MedCity News
DECEMBER 6, 2023
Too often, executives look to data retrospectively to understand what has happened, rather than using data prescriptively to understand what is likely to happen and, in turn, how to best respond.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTimes
DECEMBER 6, 2023
The neurological condition currently affects one in 300 people in the UK - News - PharmaTimes
MedCity News
DECEMBER 6, 2023
Recognizing and responding to this new emphasis on patient engagement isn’t easy. It requires providers to abandon a long-held model of healthcare with clinicians squarely at the center in favor of one in which the patients are in charge – and easily lost – if their wishes are not met.
pharmaphorum
DECEMBER 6, 2023
Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and generative AI (genAI) companies. The French pharma group has signed a multi-year agreement with Paris-based Aqemia, focused on the discovery of small-molecule drug candidates across multiple therapeutic categories, through the application of genAI and deep physics algorithms that can model molecular interactions.
MedCity News
DECEMBER 6, 2023
Our current system is broken. It only allows for the evaluation of symptoms and the treatment of disease. We need to adapt to the reality of an aging population and encourage everyone to age well.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
DECEMBER 6, 2023
In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. Venkatesh, who is responsible for sterile injectable manufacturing and operations within Dr Reddy’s global organisation, also emphasises the role of data analytics, artificial intelligence, and low-cost automation
MedCity News
DECEMBER 6, 2023
UI affects 78 million women in the U.S. while fecal incontinence affects 12 million. Prevalence is rising. Age and obesity are associated with increased risk of UI, and both contribute to its increased incidence. Globally, hundreds of millions of women are affected.
PharmaVoice
DECEMBER 6, 2023
This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.
MedCity News
DECEMBER 6, 2023
Many new to financing negotiations try to paint a rosy picture and offer unrealistic terms or revenue expectations to improve a soured relationship. This will quickly backfire and result in defaults, which not only incurs additional costs, but can rupture trust and spoil relationships.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmExec
DECEMBER 6, 2023
An overview of the nine biggest developments to expect across the healthcare industry in the year ahead.
PharmaTimes
DECEMBER 6, 2023
The commitments will make health systems faster, simpler and fairer for patients - News - PharmaTimes
pharmaphorum
DECEMBER 6, 2023
Daiichi Sankyo unit claims $182m in Novartis patent dispute Phil.
Pharmaceutical Commerce
DECEMBER 6, 2023
Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Clarivate
DECEMBER 6, 2023
By the year 2030, it is likely the legal space will look and operate differently to today, resulting in reshaping the way IP professionals at law firms and in-house councils work. What could this mean for the future of the IP legal profession? Today’s global workforce is experiencing significant, swift and continuous shifts. Customer needs are evolving.
pharmaphorum
DECEMBER 6, 2023
Merck pummelled as MS hope fenebrutinib dies in phase 3 Phil.
Pharmaceutical Commerce
DECEMBER 6, 2023
While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.
Clarify Health
DECEMBER 6, 2023
The strategic use of competitive intelligence data is increasingly becoming a crucial factor for healthcare payers looking to make informed decisions around strategic market expansion and strengthen their market position. By harnessing comprehensive data analytics, health plans can gain valuable insights into competitor benchmarking, enabling them to adapt and refine their strategies to stay ahead of the game.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
327 
Let's personalize your content